Precautions when taking Rituximab

Rituximab (Rituximab) is a strictly controlled drug after it is launched in China. Its use must be carried out by doctors and medical staff. Before starting rituximab treatment, all patients should be screened for HBV infection by measuring HBsAg and anti-HBc. For patients with RA, GPA or MPA, complete blood cell count and platelet count should be performed every 2-4 months during treatment. During treatment with rituximab, patients should pay attention to the occurrence of adverse events such as infusion reactions, mucocutaneous reactions, hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infection, cardiovascular events, nephrotoxicity, intestinal obstruction and perforation.